Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
WBA Stock Forecast 2026-2027
$11.98
Current Price
$10.35B
Market Cap
Buy 1
Hold 7
Sell 0
Wall St Analyst Ratings
Distance to WBA Price Targets
+25.2%
To High Target of $15.00
-4.4%
To Median Target of $11.45
-8.2%
To Low Target of $11.00
WBA Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
-4.3%
1 Year Change
0.0%
Year-to-Date Change
-9.6%
From 52W High of $13.25
+48.3%
From 52W Low of $8.08
📊 TOP ANALYST CALLS
Did WBA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Walgreens is one of their latest high-conviction picks.
Latest WBA Stock Price Targets & Analyst Predictions
Based on our analysis of 27 Wall Street analysts, WBA has a neutral consensus with a median price target of $11.45 (ranging from $11.00 to $15.00). The overall analyst rating is Buy (6.5/10). Currently trading at $11.98, the median forecast implies a -4.4% downside. This outlook is supported by 1 Buy, 7 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Lisa Gill at JP Morgan, projecting a 25.2% upside. Conversely, the most conservative target is provided by Allen Lutz at B of A Securities, suggesting a 8.2% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
WBA Analyst Ratings
1
Buy
7
Hold
0
Sell
WBA Price Target Range
Low
$11.00
Average
$11.45
High
$15.00
Current: $11.98
Latest WBA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for WBA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 28, 2025 | Deutsche Bank | George Hill | Sell | Downgrade | $9.00 |
| Jan 31, 2025 | Truist Securities | David Macdonald | Hold | Maintains | $12.00 |
| Jan 16, 2025 | Truist Securities | David Macdonald | Hold | Maintains | $13.00 |
| Jan 15, 2025 | RBC Capital | Ben Hendrix | Sector Perform | Maintains | $12.00 |
| Jan 13, 2025 | Evercore ISI Group | Elizabeth Anderson | In-Line | Maintains | $12.00 |
| Jan 13, 2025 | B of A Securities | Allen Lutz | Underperform | Maintains | $8.50 |
| Dec 4, 2024 | RBC Capital | Ben Hendrix | Sector Perform | Maintains | $9.00 |
| Oct 23, 2024 | Jefferies | Brian Tanquilut | Hold | Maintains | $9.00 |
| Oct 22, 2024 | TD Cowen | Charles Ryhee | Buy | Maintains | $14.00 |
| Oct 17, 2024 | UBS | Kevin Caliendo | Neutral | Maintains | $10.00 |
| Oct 16, 2024 | Barclays | Steve Valiquette | Underweight | Maintains | $8.00 |
| Oct 16, 2024 | Evercore ISI Group | Elizabeth Anderson | In-Line | Maintains | $10.00 |
| Oct 11, 2024 | Morgan Stanley | Erin Wright | Underweight | Maintains | $7.00 |
| Oct 7, 2024 | Truist Securities | David Macdonald | Hold | Maintains | $10.00 |
| Sep 12, 2024 | TD Cowen | Charles Ryhee | Buy | Maintains | $16.00 |
| Sep 4, 2024 | B of A Securities | Allen Lutz | Underperform | Maintains | $7.50 |
| Aug 30, 2024 | JP Morgan | Lisa Gill | Overweight | Maintains | $15.00 |
| Jul 23, 2024 | Barclays | Steve Valiquette | Underweight | Maintains | $7.00 |
| Jul 3, 2024 | UBS | Kevin Caliendo | Neutral | Maintains | $12.00 |
| Jul 2, 2024 | RBC Capital | Ben Hendrix | Sector Perform | Maintains | $13.00 |
Walgreens Boots Alliance Inc. (WBA) Competitors
The following stocks are similar to Walgreens based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Walgreens Boots Alliance Inc. (WBA) Financial Data
Walgreens Boots Alliance Inc. has a market capitalization of $10.35B with a P/E ratio of 27.1x. The company generates $154.58B in trailing twelve-month revenue with a -4.1% profit margin.
Revenue growth is +7.2% quarter-over-quarter, while maintaining an operating margin of +0.7% and return on equity of -69.6%.
Valuation Metrics
Market Cap
$10.35B
Enterprise Value
$39.67B
P/E Ratio
27.1x
PEG Ratio
-0.2x
Price/Sales
0.1x
Growth & Margins
Revenue Growth (YoY)
+7.2%
Gross Margin
+16.7%
Operating Margin
+0.7%
Net Margin
-4.1%
EPS Growth
+7.2%
Financial Health
Cash/Price Ratio
+8.0%
Current Ratio
0.6x
Debt/Equity
409.9x
ROE
-69.6%
ROA
+0.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Walgreens Boots Alliance Inc. (WBA) Business Model
About Walgreens Boots Alliance Inc.
What They Do
Pharmaceutical and health retail provider.
Business Model
The company operates a network of retail drugstores, selling a variety of health and wellness products, medications, and personalized care services. It generates revenue through the sale of prescription medications and other health-related products, while also integrating digital innovations to enhance customer experiences.
Additional Information
Walgreens Boots Alliance Inc. has a strong presence in both the U.S. and international markets, particularly in Europe under the Boots brand. The company is recognized for its stability and comprehensive distribution capabilities, positioning it as a key player in the healthcare sector and a barometer for retail pharmacy industry trends.
Company Information
Sector
Healthcare
Industry
Pharmaceutical Retailers
Employees
193,000
CEO
Mr. Timothy C. Wentworth
Country
United States
IPO Year
1985
Website
www.walgreensbootsalliance.comWalgreens Boots Alliance Inc. (WBA) Latest News & Analysis
Latest News
Quick Summary
Federal rules on mifepristone remain unchanged post-Trump's election, but FDA safety reviews and state lawsuits are impacting the $6.9 billion abortion drug market reliant on telehealth.
Why It Matters
Uncertainty around mifepristone regulations and state-level lawsuits could impact the $6.9 billion abortion drug market, affecting companies involved in telehealth and pharmaceutical delivery.
Source: CNBC
Market Sentiment:
Negative
Walgreens Unwraps Holiday Savings for 2025
1 month ago
Quick Summary
Walgreens announces holiday savings from Black Friday to Christmas, offering low prices on gifts, toys, games, beauty products, and essentials to enhance affordability for shoppers.
Why It Matters
Walgreens' holiday promotions indicate strong consumer engagement and potential revenue growth. Increased sales during the holiday season can positively impact the company's financial performance, attracting investor interest.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Walgreens is launching a Pharmacy Patient Advisory Board to incorporate patient feedback in its pharmacy services, focusing on chronic and complex conditions. Rina Shah will chair the board.
Why It Matters
Walgreens' formation of a Patient Advisory Board signals a commitment to patient-centric services, potentially enhancing customer loyalty and improving financial performance in the pharmacy sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Walgreens has introduced the 2025-2026 Respiratory Index, an online tool that tracks flu and COVID-19 activity using data from its locations, enhancing insights into respiratory illness trends in the U.S.
Why It Matters
Walgreens' Respiratory Index enhances insight into flu and COVID-19 trends, potentially influencing healthcare demand and sales. This can affect stock performance and market positioning.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Walgreens has launched an expanded party supply assortment nationwide, making it easier for customers to prepare for occasions. This initiative targets the growing trend of casual celebrations.
Why It Matters
Walgreens' expanded party supply offerings tap into consumer trends, potentially boosting sales and foot traffic, which can positively impact revenue and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Walgreens appointed Mike Motz as CEO following its acquisition by Sycamore Partners, initiating a new phase for the company amid competitive challenges.
Why It Matters
Mike Motz's appointment signals a strategic shift for Walgreens post-acquisition, potentially enhancing competitiveness and driving growth, impacting investor sentiment and stock performance.
Source: Reuters
Market Sentiment:
Neutral
Frequently Asked Questions About WBA Stock
What is Walgreens Boots Alliance Inc.'s (WBA) stock forecast for 2026?
Based on our analysis of 27 Wall Street analysts, Walgreens Boots Alliance Inc. (WBA) has a median price target of $11.45. The highest price target is $15.00 and the lowest is $11.00.
Is WBA stock a good investment in 2026?
According to current analyst ratings, WBA has 1 Buy ratings, 7 Hold ratings, and 0 Sell ratings. The stock is currently trading at $11.98. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for WBA stock?
Wall Street analysts predict WBA stock could reach $11.45 in the next 12 months. This represents a -4.4% decrease from the current price of $11.98. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Walgreens Boots Alliance Inc.'s business model?
The company operates a network of retail drugstores, selling a variety of health and wellness products, medications, and personalized care services. It generates revenue through the sale of prescription medications and other health-related products, while also integrating digital innovations to enhance customer experiences.
What is the highest forecasted price for WBA Walgreens Boots Alliance Inc.?
The highest price target for WBA is $15.00 from Lisa Gill at JP Morgan, which represents a 25.2% increase from the current price of $11.98.
What is the lowest forecasted price for WBA Walgreens Boots Alliance Inc.?
The lowest price target for WBA is $11.00 from Allen Lutz at B of A Securities, which represents a -8.2% decrease from the current price of $11.98.
What is the overall WBA consensus from analysts for Walgreens Boots Alliance Inc.?
The overall analyst consensus for WBA is neutral. Out of 27 Wall Street analysts, 1 rate it as Buy, 7 as Hold, and 0 as Sell, with a median price target of $11.45.
How accurate are WBA stock price projections?
Stock price projections, including those for Walgreens Boots Alliance Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 18, 2026 2:36 AM UTC